Investor Presentaiton

Significant advancements across our broader pipeline and portfolio Vaccines • V116: ⚫ STRIDE-3 data will be presented at World Vaccine Congress West Coast on November 28th • If approved, V116 would be the first pneumococcal conjugate vaccine designed to address serotypes responsible for the majority of adult invasive pneumococcal disease Immunology • MK-7240: . • Beginning to enroll patients in Phase 3 study for treatment of patients with ulcerative colitis Cardiometabolic Sotatercept: . . • Presented post-hoc analysis from STELLAR and interim analysis from SOTERIA, an open label extension study in PAH FDA granted priority review for Biologics License Application with target action date of March 26th ⚫ Completed submission to EMA in the European Union ⚫ MK-0616: . . Initiated Phase 3 CORALreef Lipids study in broad patient population with hypercholesterolemia • Initiated Phase 3 CORALreef HeFH study for patients with heterozygous familial hypercholesterolemia . Enrollment has begun for CORALreef Outcomes study measuring time to first occurrence of major atherosclerotic cardiovascular events in high risk patients MERCK 25

View entire presentation